Literature DB >> 21932423

XMRV accelerates cellular proliferation, transformational activity, and invasiveness of prostate cancer cells by downregulating p27(Kip1).

Jui Pandhare-Dash1, Chinmay K Mantri, Yuanying Gong, Zhenbang Chen, Chandravanu Dash.   

Abstract

BACKGROUND: Xenotropic murine leukemia virus-related retrovirus (XMRV) is a recently discovered gammaretrovirus that was originally detected in prostate tumors. However, a causal relationship between XMRV and prostate cancer remains controversial due to conflicting reports on its etiologic occurrence. Even though gammaretroviruses are known to induce cancer in animals, a mechanism for XMRV-induced carcinogenesis remains unknown. Several mechanisms including insertional mutagenesis, proinflammatory effects, oncogenic viral proteins, immune suppression, and altered epithelial/stromal interactions have been proposed for a role of XMRV in prostate cancer. However, biochemical data supporting any of these mechanisms are lacking. Therefore, our aim was to evaluate a potential role of XMRV in prostate carcinogenesis.
METHODS: Growth kinetics of prostate cancer cells are conducted by MTT assay. In vitro transformation and invasion was carried out by soft agar colony formation, and Matrigel cell invasion assay, respectively. p27(Kip1) expression was determined by Western blot and MMP activation was evaluated by gelatin-zymography. Up-regulation of miR221 and miR222 expression was examined by real-time PCR.
RESULTS: We demonstrate that XMRV infection can accelerate cellular proliferation, enhance transformation, and increase invasiveness of slow growing prostate cancer cells. The molecular basis of these viral induced activities is mediated by the downregulation of cyclin/cyclin dependent kinase inhibitor p27(Kip1) . Downstream analyses illustrated that XMRV infection upregulates miR221 and miR222 expression that target p27(Kip1) mRNA.
CONCLUSIONS: We propose that downregulation of p27(Kip1) by XMRV infection facilitates transition of G1 to S, thereby accelerates growth of prostate cancer cells. Our findings implicate that if XMRV is present in humans, then under appropriate cellular microenvironment it may serve as a cofactor to promote cancer progression in the prostate.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21932423      PMCID: PMC3275676          DOI: 10.1002/pros.21491

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  47 in total

Review 1.  Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis.

Authors:  S Curran; G I Murray
Journal:  Eur J Cancer       Date:  2000-08       Impact factor: 9.162

2.  Avian hemangioma retrovirus induces cell proliferation via the envelope (env) gene.

Authors:  A Alian; D Sela-Donenfeld; A Panet; A Eldor
Journal:  Virology       Date:  2000-10-10       Impact factor: 3.616

3.  Recombinant origin of the retrovirus XMRV.

Authors:  Tobias Paprotka; Krista A Delviks-Frankenberry; Oya Cingöz; Anthony Martinez; Hsing-Jien Kung; Clifford G Tepper; Wei-Shau Hu; Matthew J Fivash; John M Coffin; Vinay K Pathak
Journal:  Science       Date:  2011-05-31       Impact factor: 47.728

Review 4.  Oncogenic transformation by the jaagsiekte sheep retrovirus envelope protein.

Authors:  S-L Liu; A D Miller
Journal:  Oncogene       Date:  2006-08-14       Impact factor: 9.867

5.  Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse.

Authors:  A Di Cristofano; M De Acetis; A Koff; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  2001-02       Impact factor: 38.330

Review 6.  Diverse ways to control p27Kip1 function: miRNAs come into play.

Authors:  Carlos le Sage; Remco Nagel; Reuven Agami
Journal:  Cell Cycle       Date:  2007-08-16       Impact factor: 4.534

7.  Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer.

Authors:  Nicole Fischer; Olaf Hellwinkel; Claudia Schulz; Felix K H Chun; Hartwig Huland; Martin Aepfelbacher; Thorsten Schlomm
Journal:  J Clin Virol       Date:  2008-09-27       Impact factor: 3.168

8.  Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer.

Authors:  Sanggu Kim; Namshin Kim; Beihua Dong; David Boren; Serena A Lee; Jaydip Das Gupta; Christina Gaughan; Eric A Klein; Christopher Lee; Robert H Silverman; Samson A Chow
Journal:  J Virol       Date:  2008-08-06       Impact factor: 5.103

9.  miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1.

Authors:  Silvia Galardi; Neri Mercatelli; Ezio Giorda; Simone Massalini; Giovanni Vanni Frajese; Silvia Anna Ciafrè; Maria Giulia Farace
Journal:  J Biol Chem       Date:  2007-06-14       Impact factor: 5.157

10.  Differential regulation of p27(Kip1) expression by mitogenic and hypertrophic factors: Involvement of transcriptional and posttranscriptional mechanisms.

Authors:  M J Servant; P Coulombe; B Turgeon; S Meloche
Journal:  J Cell Biol       Date:  2000-02-07       Impact factor: 10.539

View more
  10 in total

Review 1.  Patient-derived xenografts as in vivo models for research in urological malignancies.

Authors:  Takahiro Inoue; Naoki Terada; Takashi Kobayashi; Osamu Ogawa
Journal:  Nat Rev Urol       Date:  2017-02-21       Impact factor: 14.432

Review 2.  XMRV and prostate cancer--a 'final' perspective.

Authors:  Karen S Sfanos; Amanda L Aloia; Angelo M De Marzo; Alan Rein
Journal:  Nat Rev Urol       Date:  2012-01-10       Impact factor: 14.432

3.  In-depth investigation of archival and prospectively collected samples reveals no evidence for XMRV infection in prostate cancer.

Authors:  Deanna Lee; Jaydip Das Gupta; Christina Gaughan; Imke Steffen; Ning Tang; Ka-Cheung Luk; Xiaoxing Qiu; Anatoly Urisman; Nicole Fischer; Ross Molinaro; Miranda Broz; Gerald Schochetman; Eric A Klein; Don Ganem; Joseph L Derisi; Graham Simmons; John Hackett; Robert H Silverman; Charles Y Chiu
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

4.  Absence of XMRV and closely related viruses in primary prostate cancer tissues used to derive the XMRV-infected cell line 22Rv1.

Authors:  Jaydip Das Gupta; Ka-Cheung Luk; Ning Tang; Christina Gaughan; Eric A Klein; Eugene S Kandel; John Hackett; Robert H Silverman
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

5.  A new tumour suppression mechanism by p27Kip1: EGFR down-regulation mediated by JNK/c-Jun pathway inhibition.

Authors:  Yong Fang; Yihong Wang; Yulei Wang; Yan Meng; Junlan Zhu; Honglei Jin; Jingxia Li; Dongyun Zhang; Yonghui Yu; Xue-Ru Wu; Chuanshu Huang
Journal:  Biochem J       Date:  2014-11-01       Impact factor: 3.857

6.  XMRV induces cell migration, cytokine expression and tumor angiogenesis: are 22Rv1 cells a suitable prostate cancer model?

Authors:  Kristin Stieler; Udo Schumacher; Andrea Kristina Horst; Nicole Fischer
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

7.  Infection of Xenotransplanted Human Cell Lines by Murine Retroviruses: A Lesson Brought Back to Light by XMRV.

Authors:  Heidi A Hempel; Kathleen H Burns; Angelo M De Marzo; Karen S Sfanos
Journal:  Front Oncol       Date:  2013-06-17       Impact factor: 6.244

8.  Xenotropic MLV envelope proteins induce tumor cells to secrete factors that promote the formation of immature blood vessels.

Authors:  Meera Murgai; James Thomas; Olga Cherepanova; Krista Delviks-Frankenberry; Paul Deeble; Vinay K Pathak; David Rekosh; Gary Owens
Journal:  Retrovirology       Date:  2013-03-27       Impact factor: 4.602

Review 9.  The saga of XMRV: a virus that infects human cells but is not a human virus.

Authors:  Maribel Arias; Hung Fan
Journal:  Emerg Microbes Infect       Date:  2014-04-09       Impact factor: 19.568

10.  miRNA‑222 promotes liver cancer cell proliferation, migration and invasion and inhibits apoptosis by targeting BBC3.

Authors:  Zhichun Liu; Jingwu Sun; Bin Liu; Mengjie Zhao; Entao Xing; Cunshu Dang
Journal:  Int J Mol Med       Date:  2018-04-20       Impact factor: 4.101

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.